Industry Supported Sessions

THURSDAY, DECEMBER 13, 2018 | 11.00 – 12.30

Does Psoriasis Treatment Alter the Risk of Comorbidities? Examining the Evidence
Symposium supported by Eli Lilly

Chair: Eyerich, Kilian, Munich, Germany

11.00 – 11.10 Psoriasis and Comorbidities: An Overview
Eyerich, Kilian, Munich, Germany
11.10 – 11.25 The Role of Cytokines in the Pathogenesis of Psoriasis and Associated Comorbidities
Brunner, Patrick, Vienna, Austria
11.25 – 11.45 Does Psoriasis Treatment affect Cardiovascular Disease?
Joel Gelfand, Philadelphia, PA, USA
11.45 – 12.05 The Impact of Treatment Choice on Comorbidities in Psoriasis
Kristian Reich, Berlin, Germany
12.05 – 12.25 Panel Discussion and Audience Q&A: Implications for Psoriasis Management
All faculty
12.25 – 12.30 Concluding Remarks and Close
Eyerich, Kilian, Munich, Germany

 

FRIDAY, DECEMBER 14, 2018 | 08.00 – 09.30

Discover the potential: exploring new frontiers of IL-23 inhibitors
Symposium supported by Janssen

Chair: Antonio Costanzo, Milano, Italy & Kilian Eyerich, Munich, Germany

08.30 – 08.35 Welcome and introduction
Antonio Costanzo, Milano, Italy
08.35 – 08.55 Advancing the science of psoriasis: the underlying pathology and the role IL-23
Antonio Costanzo, Milano, Italy
08.55 – 09.15 New horizons in managing psoriasis:  individualizing care one patient at a time
Kilian Eyerich, Munich, Germany
09.15 – 09.25 Interactive Q&A session
Antonio Costanzo, Milano, Italy
&
Kilian Eyerich, Munich, Germany
09.25 – 09.30 Summary and closing
Kilian Eyerich, Munich, Germany

 

FRIDAY, DECEMBER 14, 2018 | 12.00 – 13.30

THE GREAT DEBATE:
Should the Treatment Paradigm for Mild to Moderate Atopic Dermatitis (AD) Evolve?
Symposium supported by Pfizer

Faculty T.B.A

 

SATURDAY, DECEMBER 15, 2018 | 08.00 – 09.30

Atopic Dermatitis and Beyond: Pathogenic and Therapeutic Advances
Symposium supported by Sanofi

08.00 – 08.10 Introduction
Emma Guttman, New York, USA
08.10 – 08.35 Atopic Dermatitis: Emerging as a cytokine-driven disease and novel therapeutic developments
Emma Guttman, New York, USA
08.35 – 08.55 Pediatric atopic dermatitis–pathogenic and therapeutic advances and implications for the atopic march
Patrick Brunner, Vienna, Austria
08.55 – 09.20 Th2 Inhibition beyond atopic dermatitis
Frank O. Nestle, Boston, USA
09.20 – 09.30 Panel Discussion
Emma Guttman, Frank O. Nestle, Patrick Brunner